Bing-Neel综合征的诊断和治疗进展

IF 0.9 Q4 HEMATOLOGY

Hemato Pub Date : 2022-11-29 DOI:10.3390/hemato3040051

Evangeline Y. Wong, S. D’Sa, M. Minnema, J. Castillo, D. Talaulikar

{"title":"Bing-Neel综合征的诊断和治疗进展","authors":"Evangeline Y. Wong, S. D’Sa, M. Minnema, J. Castillo, D. Talaulikar","doi":"10.3390/hemato3040051","DOIUrl":null,"url":null,"abstract":"Bing–Neel syndrome (BNS) is a rare neurological complication of Waldenström macroglobulinaemia. We highlight key issues in clinical presentation, diagnosis, and treatment while focusing on new and emerging therapies available for patients diagnosed with BNS. It is anticipated that further development of Bruton Tyrosine Kinase (BTK) inhibitors and less toxic chemoimmunotherapies will improve treatment delivery and response.","PeriodicalId":93705,"journal":{"name":"Hemato","volume":" ","pages":""},"PeriodicalIF":0.9000,"publicationDate":"2022-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Bing–Neel Syndrome: Update on Diagnosis and Treatment\",\"authors\":\"Evangeline Y. Wong, S. D’Sa, M. Minnema, J. Castillo, D. Talaulikar\",\"doi\":\"10.3390/hemato3040051\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Bing–Neel syndrome (BNS) is a rare neurological complication of Waldenström macroglobulinaemia. We highlight key issues in clinical presentation, diagnosis, and treatment while focusing on new and emerging therapies available for patients diagnosed with BNS. It is anticipated that further development of Bruton Tyrosine Kinase (BTK) inhibitors and less toxic chemoimmunotherapies will improve treatment delivery and response.\",\"PeriodicalId\":93705,\"journal\":{\"name\":\"Hemato\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2022-11-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hemato\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3390/hemato3040051\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hemato","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/hemato3040051","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

Bing-Neel综合征(BNS)是一种罕见的神经系统并发症Waldenström巨球蛋白血症。我们强调临床表现、诊断和治疗方面的关键问题，同时关注BNS患者可用的新疗法。预计布鲁顿酪氨酸激酶(BTK)抑制剂的进一步开发和毒性较小的化学免疫疗法将改善治疗的递送和反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Bing–Neel Syndrome: Update on Diagnosis and Treatment

Bing–Neel syndrome (BNS) is a rare neurological complication of Waldenström macroglobulinaemia. We highlight key issues in clinical presentation, diagnosis, and treatment while focusing on new and emerging therapies available for patients diagnosed with BNS. It is anticipated that further development of Bruton Tyrosine Kinase (BTK) inhibitors and less toxic chemoimmunotherapies will improve treatment delivery and response.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Hemato

CiteScore

1.30

自引率

0.00%

发文量

审稿时长

11 weeks